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Abstract
Purpose—Head and neck squamous cell carcinoma (HNSCC) remains a devastating disease, and 
FA gene mutations and transcriptional repression are common. Invasive tumor behaviour is 
associated with poor outcome, but relevant pathways triggering invasion are poorly understood. 
There is a significant need to improve our understanding of genetic pathways and molecular 
mechanisms driving advanced tumor phenotypes, in order to develop tailored therapies. Here we 
sought to investigate the phenotypic and molecular consequences of FA pathway loss in HNSCC 
cells.
Experimental Design—Using sporadic HNSCC cell lines with and without FA gene 
knockdown, we sought to characterize the phenotypic and molecular consequences of FA 
deficiency. FA pathway inactivation was confirmed by the detection of classical hallmarks of FA 
following exposure to DNA crosslinkers. Cells were subjected to RNA sequencing with qRT-PCR 
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validation, followed by cellular adhesion and invasion assays in the presence and absence of DNA-
PK and Rac1 inhibitors.
Results—We demonstrate that FA loss in HNSCC cells leads to cytoskeletal reorganization and 
invasive tumor cell behavior in the absence of proliferative gains. We further demonstrate that 
cellular invasion following FA loss is mediated, at least in part, through NHEJ-associated DNA-
dependent protein kinase (DNA-PK) and downstream Rac1 GTPase activity.
Conclusions—These findings demonstrate that FA loss stimulates HNSCC cell motility and 
invasion, and implicate a targetable DNA-PK/Rac1 signaling axis in advanced tumor phenotypes.
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Introduction
In the general population, HNSCC is associated with smoking, alcohol consumption and 
HPV infection, and represents the sixth leading type of cancer worldwide, with an annual 
incidence of 500,000. More than half of sporadic HNSCCs are diagnosed at locally 
advanced or metastatic stages, and approximately 50% of treated patients relapse with local 
or distant metastasis, both bearing poor rates of remission (1, 2). Unfortunately, decades of 
research have not improved HNSCC outcomes significantly, and the classic therapeutic 
option, a combination of surgery, radiation and chemotherapy, leaves patients permanently 
disfigured. Thus, there is a need to improve our understanding of the biological processes 
driving local invasiveness, and develop novel approaches the treatment of late stage tumors. 
Previous exome sequencing data demonstrated that 11% of HPV+ and HPV− HNSCCs 
harbor non-synonymous mutations in FA DNA repair genes (3). In addition to classical loss-
of-function mutations, transcriptional repression of FANCB, FANCC, FANCF, FANCJ, and 
FANCM (eg, by promoter methylation) has been noted in dysplastic HN tissue and HNSCC 
(4, 5). This suggests that loss of FA pathway function can provide a selective advantage to 
HNSCC cells. However, the underlying biological mechanisms - aside from genome 
instability - remain poorly understood.
Major advances in understanding how defective DNA repair pathways contribute to 
tumorigenesis have been achieved by studying DNA repair deficiency syndromes that often 
manifest during the first years of life (6). Fanconi anemia (FA) is a rare inherited disorder 
where every cell of an affected individual is exquisitely sensitive to DNA cross-linking 
agents including mitomycin C or cisplatin (for reviews on mechanisms and disease 
manifestations see (7, 8), and references within). Clinically, patients with FA are 
characterized by frequent congenital abnormalities, early progressive bone marrow failure, 
and a high propensity for developing malignancies, especially acute myeloid leukemia, and 
squamous cell carcinoma of the head and neck, esophageal and anogenital regions. In fact, 
FA patients with HNSCCs are usually diagnosed at a young age with advanced tumor stages 
that have a poor prognosis (9, 10). FA has been associated with recessive mutations in one of 
19 FA genes (11), which play a crucial role in triggering and coordinating fundamental 
mechanisms of DNA repair for the maintenance of genome instability. When intact, the FA 
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core complex, composed of the protein products of eight FA genes including FANCA, is 
assembled at the site of DNA damage and triggers monoubiquitination of the central and 
evolutionarily conserved pathway members FANCD2 and FANCI by the E3 ligase FANCL. 
The activated FANCD2/FANCI dimer then stabilizes the stalled replication fork at the 
crosslink and coordinates the activity of nucleases, TLS polymerases, and homologous 
recombination factors. Genes of the homologous recombination (HR) pathway, where bi-
allelic mutations clinically cause FA-like syndromes, are BRIP1/FANCJ, BRCA1/FANCS, 
BRCA2/FANCD1, PALB2/FANCN and RAD51C/FANCO. Cells with bi-allelic mutations 
in FA genes can compensate for their HR defects by over-activating the error-prone non-
homologous end joining (NHEJ) pathway (12, 13), thus triggering inappropriate DNA 
repair. Individuals with heterozygous loss-of-function germ-line mutations in DNA repair 
genes also are at an increased risk for tumors, due to the loss of the wild-type allele in the 
malignant cells (6). Here, heterozygous germ-line defects in the ‘late’ genes of the FA 
pathway (FANCD1/J/N/O/Q/S) are predominantly associated with the development of 
hereditary breast/ovarian and pancreatic cancer (14, 15). Furthermore, even sporadic tumors 
in patients with no family history of cancer frequently harbor mutations in DNA repair genes 
(3, 16–18).
Several lines of evidence suggest that FA pathway loss in the epidermis, in contrast to the 
hematopoietic system, promotes growth in the basal stem and progenitor cell compartment. 
First, in murine models, genetic loss of Fancd2 cooperated with transgenic HPV16 E7 
expression targeted to basal epithelial cells to promote the development of HNSCC (19). 
Importantly, Fancd2 loss alone was already sufficient for a subtle yet consistent increase in 
basal cell proliferation in E7-negative control mice, thus highlighting a pro-proliferative role 
for FA pathway defects in the normal epidermis and in an HPV negative environment. 
Second, using HPV immortalized human keratinocytes, we have previously reported that 
FANCA or FANCD2 knockdown drive proliferation and HPV E7-dependent hyperplasia in 
3D organotypic epithelial raft but not in 2D keratinocyte culture systems (20). Third, we 
have recently reported that defects in the FA pathway stimulate HPV genome amplification 
and accumulation of the HPV E7 oncoprotein with concomitant cellular proliferation (21, 
22). Forth, FA patient-derived HNSCC cell lines were shown to harbor either similar or 
increased stem cell populations when compared to sporadic HNSCC lines, using tumor 
sphere formation, CD44 positivity or ALDH1 status as experimental end points (23, 24).
In order to define the functional effects of acquired FA deficiency in HNSCC cells, we 
generated isogenic FA HNSCC models using shRNA-mediated stable knockdown and 
rescue strategies in HPV positive and negative tumor cell lines. While depletion of the key 
FA pathway components FANCA, FANCD2 and FANCJ induced classical FA phenotypes in 
these cells when exposed to DNA crosslinkers, minor to no effects on tumor cell growth 
were observed under standard culture conditions. Surprisingly however, under these same 
conditions, FA loss caused cytoskeletal reorganization, and dramatic increases in tumor cell 
invasiveness in the absence of proliferative gains in HPV positive and negative HNSCC 
cells. Invasive properties were associated, at least in part, with increased activities of the 
NHEJ associated DNA-dependent protein kinase (DNA-PK) and the Rac1 GTPase, thus 
linking FA-associated DNA damage responses with cytoskeletal machineries. In summary, 
these data highlight new and unexpected signaling connections between the FA DNA repair 
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pathway and invasive tumor phenotypes in HNSCC. These might be targeted for the 
development of novel treatment strategies to lower mortality and improve the prognosis of 
patients with advanced HNSCCs.
Materials and Methods
Cell culture
The UM-SCC1, UM-SCC6, and UM-SCC47 cell lines were derived and maintained as 
previously described (25). All cell lines were authenticated regularly by their morphologic 
characteristics and analysis of corresponding genetic and molecular markers. Nontargeting, 
FANCD2-, FANCA- and FANCJ (TRCN49915) specific short hairpin RNA (shRNA)-
expressing lentiviral vectors were obtained through the Sigma MISSION shRNA program 
(Sigma-Aldrich) as previously described (20). The MIEG-HPV-16-E7 (GenScript 
Piscataway, NJ) construct was developed from the pMIEG3 retroviral vector, a kind gift 
from Dr. David Williams (Children’s Hospital Boston, MA), and has been described earlier. 
The EcoRI-E7-His(6)-FLAG-XhoI sequence, 
GAATTCGGCGGCCGCGCCACCATGCATGGAGATACACCTACATTGCATGAATATAT
GTTAGATTTGCAACCAGAGACAACTGATCTCTACTGTTATGAGCAATTAAATGACA
GCTCAGAGGAGGAGGATGAAATAGATGGTCCAGCTGGACAAGCAGAACCGGACA
GAGCCCATTACAATATTGTAACCTTTTGTTGCAAGTGTGACTCTACGCTTCGGTTG
TGCGTACAAAGCACACACGTAGACATTCGTACTTTGGAAGACCTGTTAATGGGCA
CACTAGGAATTGTGTGCCCCATCTGTTCAGAAACCAGACTACAAGGACGACGATG
ACAAGCATCACCATCACCATCACTAACTCGAG, was created by flanking the LXSN-
HPV16-E7 gene with primers to introduce EcoRI and and in-frame His(6)-FLAG-Stop-XhoI 
sequence. The PCR product was produced, cut, and inserted into the EcoRI and XhoI sites in 
the pMIEG vector by GenScript. RD114 pseudotype retroviruses were produced in 293T 
cells using an established protocol in the Hanenberg laboratory. Cells were transduced at 30 
to 50% confluence for a total of 4 h for retroviruses or 8 h for lentiviruses in a final 
concentration of 8 μg/ml Polybrene. For MIEG-based vectors, cells were sorted on GFP. 
Following sorting and replating, cells were then transduced with either non-targeting or 
FANCD2-specific shRNA. For the lentiviral vectors, cells were selected and carried in 1.25 
μg/ml puromycin. A fusion construct between EGFP and FANCD2 cDNA was generated 
and verified by direct sequencing (H. Hanenberg, unpublished observations). The Rac1 
inhibitor NSC23766 was a generous gift by Dr. Yi Zheng.
Cell cycle measurements
Cells were seeded for 24 hours and then either left untreated or treated for 24 hours with 
0.25μg/ml or 0.5μg/ml melphalan (Sigma-Aldrich, St. Louis, MO). Cells were trypsinized 
and 5×105 cells were washed and prepared to assess BrdU incorporation according to 
manufacturer’s instructions (APC BrdU Flow Kit, BD Pharmingen, San Jose, CA). The cells 
were pulsed with 10 μM BrdU for 45 minutes. Cell cycle profiles were detected using 
7AAD, with samples acquired on a BD FACSCanto instrument (BD Biosciences, San Jose, 
CA) and the results were analyzed using FlowJo (Treestar).
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RNA Sequencing
Individual samples were aligned to the Hg19 genome using TopHat v1.4.1. Gene 
quantification was performed with Cufflinks v2.0.0 with the “-G -u -b” parameters and the 
Ensembl gene model. Gene-level quantifications were used throughout. Data was analyzed 
with GeneSpring 12.6.1 NGS, filtering to remove duplicates, and filtering on post alignment 
read metrics to remove reads with mapping quality below 40, or with more than one match 
to genome, or failing vendor QC. Quantification was carried out with DESeq as 
normalization algorithm and threshold normalized counts to 1, baseline to median of all 
samples. We filtered to remove genes with fewer than 3 RPKM in at least one sample. 
Differential expression was determined with the Audic Claverie test (P < 0.05, FC > 1.5). 
Functional enrichment analysis was carried out with ToppGene and cytoscape figures were 
made using ToppCluster.
Western blot analysis
Whole-cell protein extracts were harvested and lysed using 1X Laemmli buffer. Blotting was 
performed as previously described (21). Antibodies used were rabbit polyclonal FANCA 
(Cascade Bioscience, Winchester, MA), rabbit polyclonal FANCD2 (Novus, Littleton, CO), 
rabbit polyclonal FANCJ (Novus, Littleton, CO), mouse monoclonal DNA-PKcs (Abcam, 
Cambridge, MA), rabbit polyclonal phospho-DNA-PKcs (S2056)(Abcam, Cambridge, MA) 
and actin (Seven Hills Bioresearch, Cincinnati, OH). For detection of HPV16 E7, a primary 
antibody mix of mouse monoclonal anti-16E7 antibody (1:150, 8C9 (Invitrogen, Grand 
Island, NY); and a 1:200 dilution of ED17 (Invitrogen, Grand Island, NY)) was used.
Three-dimensional epithelial raft cultures
Organotypic rafts were generated as described previously (20). Briefly, a total of 1×106 UM-
SCC1 cells were plated on a collagen matrix with embedded feeder fibroblasts. Exposure to 
the liquid–air interface resulted in the generation of stratified epithelium with differentiation 
properties that reflect its natural human counterpart. The tissue was fixed in 2% 
paraformaldehyde after 16 days of growth, embedded in paraffin, sectioned and 
morphologically examined by hematoxylin-and-eosin staining.
Immunofluorescence and DIC Imaging
Immunofluorescence was performed as previously described (20) using the Leica DM 
5000B. Cells were plated onto coverslips into 6-well plates at equal cell number and 
collected following 24 h of incubation. Cells were fixed in 4% paraformaldehyde and rinsed 
in PBS prior to staining with Rhodamine phalloidin (1:200; Invitrogen, Grand Island, NY) 
and DAPI to stain all nuclei. DIC images were acquired at the time of Phalloidin imaging. 
Cells on coverslips were treated overnight with 20 μM NSC23766 prior to fixation.
Invasion assays
BioCoat Matrigel transwell invasion assays were performed as per manufacturer’s 
instructions (BD Bioscience, San Jose, CA). Cells were resuspended in serum free media in 
the upper chamber and allowed to invade through Matrigel to serum containing media in the 
bottom chamber. For UMSCC-1, 1.5X105 cells were seeded per transwell while for 
Romick-Rosendale et al. Page 5
Clin Cancer Res. Author manuscript; available in PMC 2017 April 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
UMSCC-6 and UMSCC-47 2.5×105 cells were seeded. Invasion was allowed to proceed for 
22 hours prior to fixation in methanol and staining with Giemsa. Total numbers of invaded 
cells were quantified for each transwell using ImageJ.
Migration Assays
Costar transwell migration assay were performed as per manufacturer’s instructions 
(Corning Incorporated, Charlotte, NC). Briefly, cells were resuspended in serum free media 
in the upper chamber and allowed to migrate through the polycarbonate membrane to the 
serum containing media located in the bottom chamber. A total of 1.5 × 105 UM-SCC1 
NTsh and D2sh cells were seeded per transwell. Migration was allowed to proceed for 16 
hours prior to fixation in methanol and staining with Giemsa. The total number of migrating 
cells was quantified for each transwell using ImageJ. Six independent migration assay 
experiments were performed. Graphs were generated using GraphPad Prism 6 and a paired 
student t-test was applied to determine significance.
Chicken Chorioallantoic Membrane (CAM) assays
Fertilized White Leghorn chicken eggs were incubated while rotating at 37°C in a 
humidified atmosphere (>60% relative humidity). After 48 hours, 0.5mL of albumin was 
removed from each egg and the eggs were placed into a non-rotating incubation chamber at 
37°C in a humidified atmosphere. After 48 hours, the eggs were windowed to expose the 
CAM, vasculature and viable embryo. To evaluate tumor cell invasion, a thinly sliced pipette 
ring was placed on top of the chorion layer of the membrane and a 25uL suspension of 
500,000 UM-SCC1 cells that were either FA-deficient or –proficient and embedded in 
matrigel were pipetted into the ring onto the membrane. Egg shell windows were covered 
with scotch tape and the eggs were returned to the non-rotating incubator. Following an 
additional 72 hours of incubation, CAMs with tumor cells were harvested, fixed in 4% 
paraformaldehyde, processed, embedded in paraffin blocks, and sectioned. 5 micron sections 
were utilized for standard hematoxylin and eosin staining.
Rac1 activity assay
The Active Rac1 Pull-Down and Detection Kit (Thermo Scientific, Waltham, MA) was used 
to detect active Rac1 in the absence and presence of DNA-PKcs inhibitor NU7026 (Tocris 
Bioscience, Bristol, UK). Briefly, cells were plated at equal cell number and allowed to 
adhere. Cells were treated with either vehicle or 10 μM NU7026 for 24 h. Prior to 
harvesting, cells were exposed to a 30 min pulse of bleomycin (10 μg/ml). Cells were 
harvested and lysed as directed by the kit and protein concentrations were determined using 
the Pierce BCA Protein Assay Kit according to manufacturing instructions (Thermo 
Scientific, Waltham, MA). Equivalent amounts of protein were loaded onto the column and 
the protocol outlined within the assay kit was followed. Following elution of activated Rac1 
from the column, western blot analysis for Rac1-GTP was performed using the anti-Rac1 
mouse monoclonal antibody (1:1000) provided in the assay kit. GTPγS (positive control) 
and GDP (negative control) were used as controls in the pull-down assays.
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Statistics
Statistical significance was determined using two-way analysis of variance (ANOVA) with 
Sidak post hoc tests using an α value of 0.05 for all calculations using phalloidin projection 
data. All other significance was determined using a Student t-test. Statistical analyses were 
performed using GraphPad Prism 6 software.
Results
Classical FA phenotypes result from FA knockdown in HPV positive and negative HNSCC 
cancer cells
We have recently analyzed whole exome sequencing data of therapy-naïve HNSCCs (26) 
and found that a significant proportion of sporadic HNSCCs harbor somatic mutations in FA 
and FA-related genes (3). In order to confirm this with sequencing data from other patient 
cohorts, we queried The Cancer Genome Atlas (TCGA) (27) (n=306), as well as whole 
sequencing data from a set of 34 primary human HNSCCs. 11.1% and 17.6%, respectively, 
of such tumors harbored non-synonymous (N.S.) mutations in the 15 FA genes that had been 
identified at that time, FANCA, FANCB, FANCC, FANCD1 (BRCA2), FANCD2, FANCE, 
FANCF, FANCG, FANCI, FANCJ, FANCL, FANCM, FANCN, FANCP, and FANCO (Fig. 
1a). In order to explore possible biological effects of FA loss in systems mimicking HPV+ 
and HPV− HNSCC, we created the following knockdown models using previously 
published lentiviral shRNA vectors (28). First, an HPV negative UM-SCC1 cell line was 
transduced with HPV16 E7, and subsequently knocked down for FANCD2. Second, the 
same cell line was knocked down for FANCA, FANCD2, and FANCJ in the absence of E7. 
Third, a second HPV− cell line, UM-SCC6, and an HPV+ cell line, UM-SCC47, were 
similarly knocked down for FANCA and FANCD2. Western blot analyses verified efficient 
FA protein depletion for all HNSCC cell lines transduced with either FANCA, -D2, and -J 
shRNA expression vectors (Figures 1b and S1). Cells transduced with the non-targeting 
(NTsh) control shRNA did not result in FA depletion (as expected). To ensure that FANCD2 
depletion induced classical FA phenotypes, DNA crosslinker sensitivity of knockdown 
versus control cells was quantified. FA lymphoblasts and fibroblasts predictably respond to 
melphalan exposure with a G2/M cell cycle arrest (28, 29). As expected, FANCD2-deficient 
UM-SCC1 cancer cells treated with melphalan also displayed an increase in the proportion 
of cells in G2/M when compared to control NTsh cells (Fig. 1c). FANCJ-deficient UM-
SCC1 cells responded to the melphalan treatment in a similar manner when compared to the 
FANCD2-deficient cancer cells (data not shown). UM-SCC6 and UM-SCC47 HNSCC cell 
lines depleted for FA proteins were similarly sensitive to melphalan (data not shown); thus 
FA knockdown induces characteristic hallmarks of FA in HPV positive and negative 
HNSCC cells. In order to determine the consequences of FA loss on UM-SCC1 cells grown 
under standard culture conditions, we quantified proliferation rates based on BrdU 
incorporation (Fig. 1d). FANCD2 and FANCJ loss did not increase the proliferation of UM-
SCC1 cells, but either decreased or did not change proliferation (Fig. 4d, S1b). In HPV16 E7 
expressing UM-SCC1 cells, FANCD2 loss did not affect cellular proliferation (Fig. S1c). 
Similar decreases or no effects were observed in UM-SCC6 and UM-SCC47 cell lines (data 
not shown). Taken together, FA knockdown in HNSCC cell lines did not alter and sometimes 
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reduced cellular growth under standard 2D culture conditions, and conferred classical FA 
phenotypes in the presence of DNA crosslinkers.
FA loss deregulates epithelial HNSCC morphology and cytoskeletal organization
To assess global expression patterns induced by perturbing the FA pathway, we performed 
RNA sequencing (RNASeq) of the above HPV16 E7 positive UM-SCC1 cells, either 
depleted for FANCD2 or control transduced (Fig. 1b). A number of genes were differentially 
expressed in the FANCD2sh compared to the NTsh HNSCC cells (Supplemental Table 1). 
Following identification of genes with significantly altered expression, ToppGene was used 
to perform gene ontology analysis and redundancies were eliminated. A large number of 
gene ontology hits were identified (Supplemental Table 2). Fig. 2a lists top candidate 
biological processes which – based on gene expression alterations – may be regulated by 
FANCD2 loss. In line with our previously published data wherein FA pathway loss impaired 
keratinocyte differentiation in organotypic epithelial raft models, the expression of a number 
of differentiation-associated genes was reduced by FANCD2 knockdown (Supp. Tables 1 
and 2). Importantly, this was not accompanied by the induction of proliferative gene 
signatures, in agreement with a lack of proliferative gains in the above FA HNSCC cell 
populations under standard conditions and with previously published data using patient-
derived cell lines (Fig. 1d and data not shown) (20). Among the top biological processes 
were cellular motility and invasion. Increased expression of the intermediate filament 
vimentin was noted which has already been linked to a number of cancers as a mesenchymal 
marker for invasive potential (30). Vimentin induction in FA HNSCC cells was validated by 
qRT-PCR (Fig. 2b). In contrast, the expression of other genes involved in classical epithelial-
to-mesenchymal transition (EMT), such as E-cadherin, snail1, or twist1 was not altered. 
Perhaps related to the observed regulation of genes involved in cellular motility, we observed 
a marked alteration in the expression of genes involved in cellular adhesion and locomotion 
(Fig. 2a). Further morphological examination of FA depleted UM-SCC1 cells by differential 
interference contrast (DIC) microscopy revealed a clear difference in cellular shape and 
spatial arrangement. FANCD2 and FANCJ knockdown in the UM-SCC1 cell line impaired 
SCC epithelial morphology: cells physically separated from each other but remained 
connected by intercellular projections that were largely absent in the control HNSCC cells 
(Fig. 2c). To further investigate the intercellular projections, the F-actin marker phalloidin 
was used to stain actin filaments. As shown in Fig. 2d, FANCD2 and FANCJ knockdown 
cells tended to separate but maintained long intercellular projections, in contrast to control 
cells which harbored tight epithelial cell-cell contacts. Taken together, FA pathway loss in 
HNSCC cells de-regulated transcriptomes associated with cellular motility and adhesion, 
and this was accompanied by morphological and cytoskeletal responses including the 
formation of intercellular protrusions. In order to assess the ability of FA deficient versus 
proficient tumor cells to grow as 3D tissues, we engineered 3D organotypic epithelial tumor 
rafts from NTsh or FANCD2sh UM-SCC1 cells (Fig. 2e). Interestingly, while FA-deficient 
cells were able to grow and assemble into 3D tissue, we noted their occasional presence in 
the underlying collagen matrix, a feature which was not shared by the FA-proficient 
counterparts. We therefore tested the possibility that FA-deficient cells harbored increased 
invasive properties.
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FA pathway loss in HNSCC cells promotes cellular invasion
Tumor cell invasiveness was determined directly using Matrigel transwell assays. Both 
HPV16 E7+ and E7− UM-SCC1 cells were significantly more invasive when knocked down 
for FANCD2 compared to empty vector controls (Figs. 3a and b). Invasion was not an 
indirect consequence of increased proliferation (Fig. 1d, data not shown) or increased 
cellular adhesion (Fig. S2a). Similarly, FANCA and FANCJ knockdown also stimulated 
invasion in UM-SCC1 cells (Fig. 3c). To rule out any off target effects for the lentiviral 
knockdown approach, we next expressed a shRNA-resistant FANCD2 construct in 
FANCD2sh UM-SCC1 cells (Fig. 3d). As predicted, the introduction of EGFP-FANCD2 
was sufficient to rescue UM-SCC1 FANCD2 shRNA cells from invasion (Fig. 3d). 
Expression of the EGFP-FANCD2 fusion protein was confirmed by western blot analysis on 
the right. Finally, FANCA and FANCD2 knockdown in UM-SCC6 and UM-SCC47 cells 
also stimulated tumor cell invasion (Figs. 3e and f). As expected, the increased invasiveness 
of the cancer cells correlated with increased motility seen by standard migration assays (Fig. 
S2b). In order to further assess the invasive properties of FA-deficient versus -proficient 
tumor cells, we utilized chicken chorioallantoic membrane (CAM) assays (Fig. S3). 
Interestingly, FA-deficient cells were occasionally able to invade into the chorion 
membranes of living chick embryos, and more specifically appeared to invade as cell 
clusters; however, invasion was never observed with their FA-proficient counterparts. Taken 
together, FA loss leads to a dramatic increase of invasive capacity and motility in HPV 
positive and negative HNSCC cells.
Invasion in response to FA loss requires DNA-PK activity
FA cells exhibit characteristic sensitivity to DNA crosslinkers, and defects in error-free DNA 
repair by homologous recombination (HR). These defects are accompanied, under some 
circumstances, by a corresponding increase in the activity of error-prone non-homologous 
end joining (NHEJ) pathway components (12, 13). NHEJ requires the activation of the 
catalytic subunit of DNA-dependent protein kinase (DNA-PKcs) and subsequent 
autophosphorylation on serine 2056 (31). In order to probe a possible functional 
involvement for DNA-PKcs signaling in FA-associated invasion, we first determined 
whether FANCD2- and FANCJ-deficient UM-SCC1 cells harbored activated DNA-PKcs. 
We then verified the functionality of a DNA-PK inhibitor NU7026 in this system in order to 
probe the importance of DNA-PK activity for invasion (Fig. 4a). Control cells and their 
FANCD2 and FANCJ-depleted counterparts were subjected to a pulse of bleomycin in order 
to stimulate DNA damage signaling, and the cells were then treated with vehicle or with the 
DNA-PKcs inhibitor NU7026. Cells were analyzed for activated DNA-PKcs phosphorylated 
on serine 2056. FANCD2 and particularly FANCJ loss stimulated DNA-PKcs 
phosphorylation compared to control (Fig. 4a, lanes 1–3), and autophosphorylation was 
completely eliminated by NU7026. Next, we determined whether DNA-PKcs activation was 
functionally important for FA-deficient cancer cell invasion. DNA-PKcs inhibition by 
NU7026 suppressed the invasive phenotype in FANCD2sh UM-SCC1 cells (Fig. 4b), but did 
not impair cellular viability (Fig. 4c). Importantly, DNA-PKcs inhibition also reduced 
control cell invasion under these conditions, thus indicating that DNA-PK activation 
contributes to HNSCC cell invasion. The ability of NU7026 to suppress invasion in FA-
Romick-Rosendale et al. Page 9
Clin Cancer Res. Author manuscript; available in PMC 2017 April 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
deficient cells was also observed in HPV+ FANCD2sh (Fig. S4a) and FANCAsh (Fig. S4b) 
UM-SCC47 cells.
Invasion in response to FA loss requires Rac1 GTPase activity
Ras-related small GTPase Rho/Rac/CDC42 signaling pathways are key players in cellular 
morphology and invasion (32). Because the activation of Rac1 was reported to produce 
intercellular projections similar to the ones noted for FA-deficient cells (Fig. 2) (33, 34), we 
carried out Rac1-GTP pull downs to first determine whether Rac1 is activated in FA HNSCC 
cells, and if so, to probe a possible role for DNA-PKcs in its regulation. FANCJsh 
knockdown cells were chosen based on the observation that DNA-PK activation was 
maximal in FANCJ when compared to FANCD2 knockdown cells in Fig. 4a. Interestingly, 
FANCJsh transduced UM-SCC1 cells showed increased Rac1 activity when compared with 
their NTsh control transduced counterparts (Fig. 5a, compare lanes 1 and 3). Treatment with 
DNA-PKcs inhibitor did not affect Rac1 activity in the control NTsh cells (Fig. 5a, compare 
lanes 1 and 2), but significantly lowered Rac1 activity in FANCD2sh and FANCJsh cells 
(Fig. 5a, compare lanes 3 and 4). Taken together, these results suggest that Rac1 activation 
downstream from FA loss is, at least in part, dependent upon DNA-PKcs activity. We next 
sought to examine the requirement for Rac1 GTPase activity in the characteristic 
cytoskeletal reorganization and invasion of FA-deficient HNSCC cells. We utilized 
NSC23766, a small molecule that has been shown to specifically inhibit Rac1 structural and 
functional activity but does not affect the activity of other Rho-related small GTPases (35, 
36). Interestingly, NSC23766 reduced the number of intercellular protrusions and stimulated 
cell-cell adhesion in FANCD2- and FANCJ-deficient compared to control UMSCC1 cells as 
assessed by DIC (Fig. 5b, top panel) and phalloidin staining (Fig. 5b, bottom panel and 
quantification below). To determine whether NSC23766 was also capable of suppressing 
cellular invasion in response to FANCD2 loss, FA-proficient and -deficient HNSCC cells 
were treated with NSC23766 or vehicle over the course of the transwell assay. Indeed, 
cellular invasion following FANCD2 loss was repressed by NSC23766 which did not 
significantly affect control cell invasion (Fig. 5c) or cellular growth (Fig. 5d). NSC23766 
could also suppress invasion in FA-deficient HPV+ UM-SCC47 cells (Fig. S4c). Together, 
these data demonstrate that FA loss and subsequent DNA-PK activation promote Rac1 
activity to induce cytoskeletal aberrations and invasive tumor phenotypes in HNSCC cells 
(see Fig. 5e for a working model).
Discussion
Each year, approximately 40,000 new patients are diagnosed with head and neck cancer, 
predominantly HNSCC, in the United States, and this number continues to rise. Two main 
causative factors in the majority of oral, oropharyngeal, and laryngeal carcinomas are 
smoking and alcohol use; however, a growing percentage of these head and neck cancers, 
approximately 25% at present, have been attributed to HPV infection (37). Cellular and 
molecular characteristics of HPV–positive and –negative HNSCCs are still being explored, 
although these are distinct biological and clinical entities (38). Herein we link the loss of the 
FA DNA repair pathway in HNSCC cells with stimulated invasive potential regardless of 
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HPV status, and uncover novel roles for DNA-PK (unrelated to DNA repair) in promoting 
Rac1 activation and invasive behavior.
Locoregional dissemination of malignant tumor cells is associated with poor outcome, and is 
crucially dependent on the migratory and invasive properties of the cancer cell. Tumor cell 
migration requires the formation of protrusions, leading edge attachment to the surrounding 
extracellular matrix, contraction of the cell to pull the cell body towards the leading edge, 
and detachment of the trailing edge. FA deficient HNSCC cells displayed expression 
changes for genes known to play key roles in cell motility, cell-cell adhesion and 
locomotion. Furthermore, we observed the presence of pronounced protrusions in FA 
deficient cells compared to their FA proficient counterparts and noted altered cell 
morphology. Together with these morphological phenotypes, we showed a significant 
increase in motility and invasion of FA deficient cells compared their FA proficient 
counterparts. Invasion was induced by the loss of either upstream (FANCA), central 
(FANCD2) and downstream (FANCJ) components of the FA pathway, and was reversible by 
the re-introduction of a knockdown-resistant construct. Together, these data support a 
scenario whereby the intact FA DNA repair machinery suppresses the transition of 
transformed to invasive HNSCC phenotypes.
DNA crosslink processing utilizes multiple repair pathways whose coordination appears to 
be a major function of the FA pathway. Recently, two reports have demonstrated that FA loss 
engages the DNA damage sensor kinase DNA-PK, a process that is likely followed by 
aberrant DNA repair by NHEJ and resulting characteristic FA chromosome pathologies. As 
such, FA proteins might govern the decision to channel double strand breaks (DSBs) into 
homologous recombination (HR) in favor of the competing DNA-PK associated error-prone 
non-homologous end-joining (NHEJ) pathway (12, 13). We show that FA loss in HNSCC 
cells increases the levels of active, auto-phosphorylated DNA-PKcs, and functionally 
implicate this DNA damage sensor in advanced HNSCC for the first time. While the nuclear 
role of DNA-PK in DNA repair is well characterized, non-canonical activities have emerged 
as well. DNA-PK has been implicated in inflammation through the phosphorylation of NF-
kB1 (39), and in metabolic gene regulation through interaction with and phosphorylation of 
USF-1 (40). Furthermore, a number of novel cytoplasmic DNA-PK substrates were 
published recently that participate in cytoskeletal regulation (41). These include members of 
the 14-3-3 protein family, vimentin, and desmoplakin. The authors showed that DNA-PK 
activation decreased motility in melanoma cell lines, in contrast to increased invasion in our 
HNSCC cells. Thus whereas advanced cancer phenotypes are regulated by DNA-PK in both 
systems, the direction of the observed regulation may be cell type specific. Such differences 
might reflect significant complexity in the regulation of cytoskeletal components by DNA-
PK. Further analysis identified a novel link between DNA-PKcs and Rac1 signaling in FA 
HNSCC cells wherein a specific DNA-PK inhibitor decreased active Rac1-GTP protein 
levels. One possible mechanism might be supported by a previous finding that DNA-PKcs 
can physically interact with the CDC42/Rac1 guanine exchange factor, ARHGEF6, in 
ovarian cancer cells (42). In addition, growing evidence supports correlations between DNA 
damage signaling and Rac1 activity (43–45), although the mechanisms and functional 
relevance of pathway cross-talk are largely unclear. Whether DNA-PKcs activates Rac1 
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directly through guanine nucleotide exchange factors or indirectly through signal 
transduction cascades is currently under investigation.
Rac1 is a well-known regulator of the cellular actin cytoskeleton, adhesion, barrier function 
and migration. Like other members of the Rho family, Rac1 cycles between GDP-bound 
inactive and GTP-bound active states (46). These GTPases are controlled by two classes of 
regulatory molecules: activating guanine nucleotide exchange factors (GEFs), and repressive 
GTPase-activating proteins (GAPs). Previously published work found that Rac1 was 
required for Kras-mediated tumorigenesis in skin epithelium and the lung (47, 48). More 
importantly, Rac1 activity strongly is associated with cell motility and tumor metastasis (49, 
50). We found that both cell morphology (protrusion formation) and cellular invasion were 
dependent upon Rac1 activation, and show a reversion of the FA deficient HNSCC cell 
phenotype to a more epithelial-like morphology following inhibition of Rac1. We also 
observed a significant decrease in cancer cell invasion of FA deficient cells following 
treatment with the Rac1 inhibitor. Taken together, these findings link the loss of the FA 
pathway with increased Rac1 activation and downstream cytoskeletal aberrations and 
aggressive invasive potential. Of importance, Rac1 inhibitors are a potential novel 
therapeutic option for sporadic HNSCC carrying FA mutations, as well as an alternative, 
non-genotoxic treatment for HNSCC in patients with FA.
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Statement of Translational Relevance
Head and neck squamous cell carcinoma (HNSCC) is a devastating cancer type with poor 
outcomes particularly when diagnosed at advanced, invasive stages. Targetable genes and 
pathways that stimulate HNSCC progression remain poorly understood. A significant 
proportion of HNSCCs harbor mutations in FA DNA repair genes. Furthermore, 
individuals with germline loss of function mutations in FA genes are uniquely 
predisposed to aggressive HNSCC development. Herein we show that loss of the FA 
pathway in HNSCC cells stimulate plasma membrane re-organization, and tumor-cell 
invasiveness in vitro and in vivo – that is reliant upon NHEJ-associated DNA-dependent 
protein kinase (DNA-PK) and Rac1 GTPase. These findings implicate this important 
DNA repair pathway in the suppression of advanced tumor phenotypes, and identify new 
treatment options tailored to FA-deficient HNSCCs.
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Figure 1. Generation of FA deficient, HPV positive and negative, HNSCC cell models
(a) The somatic mutations table (MAF file) for head and neck squamous carcinoma (HNSC) 
samples was obtained from TCGA data portal and from an independent cohort of sporadic 
HNSCC tumors from Ohio State University (OSU). Analysis of mutational data from 306 
(TCGA) and 34 (OSU) sporadic HNSCC tumors determined that 11.1% and 17.6%, 
respectively, harbored non-synonymous (N.S.) mutations in one of 16 FA genes, 
respectively. (b) UM-SCC1 HNSCC (HPV16 E7-positive and –negative) cells were knocked 
down for FANCA, FANCD2 and FANCJ, followed by western blot analysis for verification 
of protein depletion. (c) FA knockdown by shRNA transduction leads to classical FA 
phenotypes. UM-SCC1 cells were treated with melphalan, and subjected to flow cytometry 
based cell cycle analysis. The numbers listed indicate percentages of cells in G2/M 
following melphalan exposure. FANCD2-deficient cells were increased for the proportion of 
cells in G2/M when compared to the NTsh control cell population. (d) BrdU incorporation 
in FANCD2- and FANCJ-deficient compared to control UM-SCC1 cells reveals a slight 
decrease in proliferation.
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Figure 2. FA loss in HNSCC cells induces cytoskeletal and morphological alterations
(a) RNA sequencing (RNASeq) and subsequent ToppGene analysis of FANCD2-deficient 
versus control cells reveals cellular processes with significantly altered gene expression. A 
list of the top candidate biological processes is shown. (b) Verification of RNA sequencing 
gene expression results was performed on a select number of genes using qRT-PCR. qRT-
PCR also revealed that some classical EMT markers were not uniformly elevated in FA-
deficient HNSCCs, with the exception of vimentin. (c) Morphological examination of FA 
depleted HNSCC cells compared to FA-proficient controls by differential interference 
contrast (DIC) microscopy shows differences in spatial arrangement and cell shape as well 
as increased intercellular protrusions in FANCD2- and FANCJ-deficient cells. (d) 
Intercellular projections were examined further by staining with the F-actin marker 
phalloidin and subsequent immunofluorescence experiments. Quantification of intercellular 
projections was performed on three independent experiments and the errors bars represent 
standard deviation. Asterisks indicate significance at *=p<0.05, **=p<0.001, and 
***=p<0.0001 (ANOVA). (e) UM-SCC1 epithelial raft culture shows UM-SCC1 
FANCD2sh knockdown cells in the underlying collagen matrix as compared to UM-SCC1 
NTsh control cells.
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Figure 3. FA loss in a panel of HPV negative and positive HNSCC cells promotes invasion
(a) UM-SCC1 cells expressing HPV16 E7 and knocked down for FANCD2, compared to 
control NTsh cells were plated to invade through Matrigel coated transwell for 22 hours. 
Invasive cells were quantified and representative images are shown. (b–c) UM-SCC1 cells 
knocked down for FANCD2, or for FANCA and FANCJ compared to control NTsh cells 
were plated to invade through a Matrigel coated transwell for 24 hours. Invasive cells were 
quantified and representative images are shown. (d) Invasion mediated by FANCD2 
depletion could be repressed by the expression of a knockdown resistant eGFP-FANCD2 
fusion gene. UM-SCC1 cells were transduced with an eGFP-FANCD2 retroviral expression 
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vector, and sorted for GFP negative cells as a control population, or sorted for cells that 
express eGFP-FANCD2. Western blot analysis confirms expression of the fusion protein in 
GFP positive, but not in GFP negative cells. Transwell assays demonstrate EGFP-FANCD2 
mediated rescue from invasion that is driven by FANCD2 loss. (e–f) UM-SCC6 and UM-
SCC47 knocked down for FANCA and FANCD2 were similarly used for transwell invasion 
assays compared to controls.
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Figure 4. DNA-PK activity promotes cellular invasiveness
(a) FA loss stimulated DNA-PKcs phosphorylation in UM-SCC1 cells. Western blot analysis 
shows activation of DNA-PKcs by phosphorylation at Ser2056 following FANCD2 and 
FANCJ loss. The functionality of the DNA-PKcs inhibitor, NU7026, was verified in the 
same cells. Cells were treated with either DMSO or NU7026 for 24 hours and exposed to a 
short 30 minute burst of bleomycin. (b) DNA-PKcs activation contributes to invasion. Cells 
were control transduced or knocked down for FANCD2, and the number of invasive cells 
was quantified following overnight incubation. Experiments were carried out in duplicate 
and standard deviation was calculated. (c) DNA-PKcs inhibition does not affect cell viability 
as is shown by visual examination of the cells.
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Figure 5. Morphological aberrations and invasive tumor phenotypes triggered by FA loss are 
dependent upon Rac1 activation
(a) Rac1-GTP pulldown assays show that DNA-PK inhibition attenuates Rac1 activation in 
FA-deficient cells. All lanes are from the same western blot. (b) The small molecule Rac1 
inhibitor NSC23766 was utilized at 20uM concentrations that did not affect cellular growth. 
To assess the effects of Rac1 inhibition on aberrant morphology and tumor cell invasion 
triggered by FA loss, UM-SCC1 cells were plated at equal densities and imaged by DIC 
microscopy prior to and following an 18 hour exposure to 20uM NSC23766 (left). 
NSC23766 treated and untreated UM-SCC1 cells were stained for phalloidin and imaged 
(right). The reduction in intercellular membrane projections following treatment with the 
Rac1 inhibitor is quantified and included below the images. (c) Invasion of NSC23766 or 
vehicle treated FA-deficient versus -proficient UM-SCC1 cells was evaluated by transwell 
assays. Experiments were carried out in duplicate and standard deviation was calculated. (d) 
UM-SCC1 exposure to NSC23766 at 15μM and 20μM concentrations did not affect cellular 
fitness and growth for the duration of the invasion assays, 22 hours. (e) A working model 
depicts the consequences of FA deficiency in HNSCC cells. Loss of FA pathway function 
results in increased DNA stress and activation of the DNA-PK sensor kinase through 
autophosphorylation on S2056. DNA-PK activity is directly or indirectly required for 
downstream Rac1 activation, and subsequent Rac1-dependent SCC cell invasion.
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